观察临床缓解率、副反应率及复发率。
Observation of the clinical remission rate, adverse effects and recurrence rate were carried out.
病人临床症状缓解率95%。
结果：治疗组缓解率明显优于对照组。
Results: The alleviation rate of the treatment group is higher than that of the control group.
泰索帝与顺铂联合可产生较佳的缓解率。
Docetaxel, when combined with cisplatin, results in very respectable response rate.
观察临床缓解率、副反应率、复发率及缓解时间。
Clinical remission rate, adverse reaction, recurrence rate and remission period were observed.
观察临床缓解率、不良反应率、复发率及缓解时间。
Clinical remission rate, adverse reaction, recurrence rate and remission time were observed.
与霍奇金氏淋巴瘤试验相似，试验主要终点是客观缓解率。
Similar to the HL trial, the trial's primary endpoint was objective response rate.
结果干预组3、6个月的抑郁症状均减轻、缓解率均增加。
Results At 3-month and 6-month, the depressive symptoms of the intervention group were…
结论MAE方案可提高老年aml的缓解率和长期无病生存率。
Conclusion MAE protocol can improve CR rate in elderly patients of AML.
结果晚期肿瘤合并上腔静脉综合征的患者症状缓解率达100%。
Results The symptom remission rate of advanced cancer patients with SVCS reached to 100%.
初发时巨核细胞计数增高及出现病态变化者缓解率低，预后不良。
Newly diagnosed patients with higher celluler count of megakaryocytes and dysmegakaryopoiesis had less complete remission rate and poor prognosis.
结果显示云南白药疼痛缓解率明显高于对照组（P＜0．01）；
The results showed that the analgesic rate of YNBY was markedly higher than that of control (P< 0. 01);
目的探讨选择性支气管动脉灌注化疗对肺癌治疗的缓解率和缓解时间。
Objective To further study the remission rate and the remission time of the patients with advanced lung cancer treated by selective bronchial arterial infusion.
次要终点包括IRC评估的总生存期(OS)和总缓解率(ORR)。
Secondary end points included overall survival (OS) and overall response rate (ORR) per IRC.
结果：经胃左动脉药物灌注后临床症状缓解明显，缓解率98.2 %。
Result: alleviate after left artery medicine of stomach affuse the clinical condition of illness obvious, alleviate the rate 98.2%.
结果二组患者的治疗后症状缓解率和食管炎镜下愈合率均无显著性差异。
Results The symptom alleviation rate and esophagitis gastroscope concrescence rate were not obviously different.
结果：从总临床客观缓解率和主要不良反应上看治疗组明显优于对照组。
Results:From the clinical eficacy and toxicity the treatment group was significantly better than the control group.
结果：比数比以缓解率30%、50%或中度疼痛缓解和停药后复发计算。
Results Odds ratios were calculated for achievement of 30%, 50%, or moderate pain relief and for withdrawals related to adverse effects.
主要研究终点为总缓解率(ORR)，采用评价标准为RECIST 1.1。
The primary end point was overall response rate (ORR) per investigator assessment (RECIST 1.1).
研究主要终点是客观缓解率，治疗后经受完全或部分癌症皱缩或消失患者的百分率。
The study’s primary endpoint was objective response rate, the percentage of patients who experienced complete or partial cancer shrinkage or disappearance after treatment.
结果：急性腹泻于疗程结束时，试验组腹泻缓解率为91.67%（44/48）；
Results:The relief rate of acute diarrhea was 91.67% (44/48) ;
超声聚焦刀具有无创安全、无并发症、癌性癌痛缓解率高、生活质量明显提高之优点。
HIFU has the merit of no complication, no invasion, safety, high remission rate and increased live quality.
结论：高剂量强度的VIP方案化疗能获得较高的有效率及完全缓解率，毒性能耐受。
Conclusion: the intensive VIP regimen can improve the efficacy of SCLC, and the toxicity was moderate.
结果总的疼痛缓解率96 .4 % ，绝大多数不良反应能缓解，病人生活质量明显提高。
Result The total remission rate of pain was 96.4%. Most adverse reaction was alleviate, the quality of life improved remarkably.
结果：总的小腿疼痛缓解率为100%，总的足部疼痛改善率为80%。总保肢率为82%。
RESULTS: the general rate of relieving pain in leg was 100%, the pain alleviated rate and limb preserved rate were 80%and 82%, respectively.
结果与结论：患者在治疗过程中的并发症和毒副反应的发生率明显减少，化疗后完全缓解率提高。
Results and Conclusion: the incidence of complications and toxic and side reaction were significantly reduced. Complete remission rate after chemotherapy was improved.
结论：激素联合MMF治疗重症HSPN缓解率高于CTX静脉冲击疗法，能更有效降低蛋白尿和血尿。
Conclusion: the combination therapy of MMF and steroid was more effective than CTX pulse therapy in patients with severe HSPN.
骨髓涂片中MRP表达阳性患者化疗缓解率54.5%低于MRP表达阴性患者95%，具有统计学差异。
The CR rate of chemotherapy was lower in patients with MRP expression than that in patients with negative expression (54.5% vs 95%).
用利妥昔单抗治疗难治性ANCA相关性血管炎时，其缓解率可达80%到90%，可能比环磷酰胺疗法更安全。
Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens.
用利妥昔单抗治疗难治性ANCA相关性血管炎时，其缓解率可达80%到90%，可能比环磷酰胺疗法更安全。
Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens.
应用推荐